Management of Heart Failure with Preserved Ejection Fraction (HFpEF) is often called the “greatest unmet need in cardiovascular medicine.” For decades, heart failure was defined by a weak, dilated pump (HFrEF). In HFpEF, however, the heart pumps out a “normal” percentage of blood, yet the patient is breathless, exhausted, and at high risk of death.
Here is a breakdown of why this paradox makes HFpEF so notoriously difficult to manage.
The Diastolic Dilemma: It’s Not a Pumping Problem
In HFrEF (Reduced EF), the heart is like a stretched-out balloon that can’t squeeze. In HFpEF, the heart is like a stiff rubber ball.
- The Issue: The left ventricle becomes thick, stiff, or scarred (fibrosis).
- The Result: While it can squeeze well enough to empty (normal EF), it cannot relax or fill properly.
- The Pressure Spike: Because the ventricle is stiff, it takes much higher pressure to force blood into it. This back-pressure travels into the lungs, causing pulmonary edema and shortness of breath, even though the “pump” looks fine on a standard echo.
A “Chameleon” Diagnosis
Unlike HFrEF, which has a clear hallmark (an EF below 40%), HFpEF is a diagnosis of exclusion.
- Comorbidities: Patients are often older and have a “perfect storm” of other issues: obesity, hypertension, Type 2 diabetes, and chronic kidney disease.
- Symptom Overlap: Shortness of breath in an 80-year-old with obesity and COPD is often attributed to age or lungs, meaning HFpEF is frequently caught late.
- The EF Trap: A “normal” EF (typically ≥ 50%) can give clinicians a false sense of security, leading to the dangerous assumption that the heart is healthy.
The Failure of “Classic” Blockbusters
For thirty years, the “Triple Therapy” (ACE inhibitors, Beta-blockers, and MRAs) saved millions of lives in HFrEF. When these same drugs were tested for HFpEF, the results were frustratingly neutral.
| Drug Class | Effect in HFrEF | Effect in HFpEF |
| Beta-Blockers | Life-saving | Often poorly tolerated (can worsen chronotropic incompetence) |
| ACEi / ARBs | Gold Standard | Minimal impact on mortality |
| ARNI (Sacubitril/Valsartan) | Revolutionary | Benefit is “borderline” or limited to specific subgroups |
The reason for this failure is that HFpEF isn’t just a heart problem; it’s a systemic inflammatory state affecting the blood vessels, kidneys, and skeletal muscle.
The Turning Tide: SGLT2 Inhibitors
The paradox began to shift with the arrival of SGLT2 inhibitors (like Empagliflozin and Dapagliflozin). These “diabetes drugs” became the first therapy to show a significant reduction in the combined risk of cardiovascular death or hospitalization for HFpEF patients.
They work not just by diuresis, but by improving metabolic efficiency and reducing the systemic inflammation that drives the stiffening of the heart muscle.
Summary of Management Challenges
- Heterogeneity: No two HFpEF patients are the same. One might be driven by obesity, another by long-standing hypertension, and another by amyloidosis.
- Exercise Intolerance: HFpEF patients have a “stiff” cardiovascular reserve. When they try to walk, their heart pressures spike instantly.
- Volume Sensitivity: They have a narrow “sweet spot.” Too much fluid and they end up in the ER; too much diuretic and their kidneys fail because the stiff heart requires some pressure to fill.